Cancer Immunotherapy
BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies currently in clinical trials,immunomodulatory antibodies and new drug targeted at cancer specific neoantigens.